PICO Portalanswers from OpenAlex & ORCID
Paul F. Robbins
ResearcherPublications, citations & collaboration network
Paul F. Robbins is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Paul F. Robbins have?
PICO Portalindexed works
Paul F. Robbins has 311 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Paul F. Robbins have?
PICO Portalcitation count
Paul F. Robbins has 44,157 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Paul F. Robbins?
PICO Portalh-index
Paul F. Robbins has an h-index of 91 in OpenAlex.
What is the i10-index of Paul F. Robbins?
PICO Portali10-index
Paul F. Robbins has an i10-index of 173 in OpenAlex.
What is the ORCID of Paul F. Robbins?
PICO Portalorcid
The ORCID for Paul F. Robbins is on the source record.
What is the OpenAlex record for Paul F. Robbins?
PICO Portalopenalex
The OpenAlex for Paul F. Robbins is on the source record.
What are the most-cited papers on Paul F. Robbins?
PICO Portalmost cited works
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, James Chih‐Hsin Yang, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Richard M. Sherry, Nicholas P. Restifo, Amy M. Hubicki, Michael R. Robinson, Mark Raffeld, Paul H. Duray, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg
Identification of essential genes for cancer immunotherapy
Shashank J. Patel, Neville E. Sanjana, Rigel J. Kishton, Arash Eidizadeh, Suman K. Vodnala, Maggie Cam, Jared J. Gartner, Lee Jia, Seth M. Steinberg, Tori N. Yamamoto, Anand S. Merchant, Gautam U. Mehta, Anna Chichura, Ophir Shalem, Eric Tran, Robert Eil, Madhusudhanan Sukumar, Eva Pérez‐Guijarro, Chi-Ping Day, Paul F. Robbins, Steven R. Feldman, Glenn Merlino, Feng Zhang, Nicholas P. Restifo
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James Chih‐Hsin Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Yong F. Li, Mona El‐Gamil, Steven A. Rosenberg